Vertaling van "humans as regards the chronic " (Nederlands → Frans) :

As for taurine, the experts emphasise that high taurine doses can result in neurological side effects. This concerns doses that are 36 times higher than the usual taurine intake by humans as regards the chronic consumption of this type of beverage and doses that are 6 times higher than the normal intake as regards their acute intake.
En ce qui concerne la taurine, les experts soulignent la possibilité d’induction d’effets secondaires de type neurologiques pour des doses élevées de taurine qui représenteraient 36 fois l’apport usuel estimé en taurine chez l’homme dans le cadre d’une prise chronique de ce type de boisson et 6 fois cet apport dans le cadre d’une prise aiguë de cette boisson.

narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September
narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September

As regards D- glucuronolactone, the SCF confirms its reservations about a daily chronic intake of 840 mg of the product (1.4 can) and an acute intake of 1 800 mg of the product (3 cans) via this type of drink, taking into account that the natural intake of D-glucuronolactone via food amounts to 1 to 2 mg/day (SCF, 2003).
Pour le D-glucuronolactone, le SCF confirme ses réserves dans le cadre d’un apport journalier chronique de 840 mg de produit (1,4 canette) et d’un apport aigu de 1.800 mg de produit (3 cannettes) via ce type de boisson et ce, tenant compte du fait que l’apport alimentaire naturel en D-glucuronolactone est de 1 à 2 mg/jour (SCF, 2003).

As regards schizophrenia, the risk of suicide is greater with male patients in the first stages of the disorder, especially with patients who were particularly dynamic before the disorder started, and with patients who suffer chronic relapses.
En ce qui concerne la schizophrénie, le risque de suicide est plus marqué chez les patients masculins, dans les premiers stades de la maladie, en particulier auprès des patients particulièrement dynamiques avant la déclaration de la maladie, et auprès des patients avec des rechutes chroniques.

As for D-glucuronolactone, the group believes that this concerns a normal human metabolite deriving from glucose, which does not involve a structural risk with regard to mutagenicity or carcinogenicity. It also holds that both this component as well as its hydrolysis product, glucuronic acid, are endogenous metabolites in humans and other mammals, that they are naturally present in various food sources and that they are quickly metabolised into innocuous products and excreted.
Pour la D-glucuronolactone, le groupe considère qu’il s’agit d’un métabolite humain normal provenant du glucose qui ne présente pas de risque structural en termes de mutagénicité ou de carcinogénicité, que pour ce composant, comme pour son produit d’hydrolyse, l’acide glucuronique, il s’agit de métabolites endogènes chez l’homme et les autres mammifères, qu’ils se trouvent à l’état naturel dans diverses sources alimentaires et qu’ils sont rapidement métabolisés en produits sans danger et excrétés.

De Europese Commissie heeft een voorstel tot “Directive of the European Parliament and of the Council amending, as regards information to the general public on medicinal products subject to medical prescription, Directive 2001l83/EC on the Community code relating to medicinal products for human use” goedgekeurd (bijlage).
La Commission européenne a déposé une proposition de “Directive of the European Parliament and of the Council amending, as regards information to the general public on medicinal products subject to medical prescription, Directive 2001/83/EC on the Community code relating to medicinal products for human use” (cf. annexe).

Novartis and Human Genome Sciences also agreed to stop further development of albinterferon alfa-2b for the treatment of chronic hepatitis C viral infection.
Novartis et Human Genome Sciences ont également convenu d’arrêter le développement d’albinterféron alfa-2b pour le traitement de l’hépatite C chronique, une infection virale.